Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD)
Edward R Smith, Darren Lee, Michael M Cai, Laurie A Tomlinson, Martin L Ford, Lawrence P McMahon, Stephen G Holt
Nephrology Dialysis Transplantation | OXFORD UNIV PRESS | Published : 2013
BACKGROUND: Chronic kidney disease (CKD) is an increasing public health issue. It is therefore potentially highly advantageous to identify patients at risk of accelerated renal progression and death. Neutrophil gelatinase-associated lipocalin (NGAL) is an established urinary biomarker for acute kidney injury, but it is not known whether adding urinary NGAL (uNGAL) measurements to conventional risk factors will improve risk assessment in the setting of chronic disease. METHODS: This is a prospective observational cohort study of 158 patients with Stage 3 or 4 CKD. The ability of baseline uNGAL to improve prediction of outcome was assessed by multivariate modelling and a number of metrics incl..View full abstract
We gratefully acknowledge the support from The Sussex Kidney Unit and the Clinical Investigation and Research Unit, Brighton and Sussex University Hospitals, UK and the Department of Renal Medicine, Eastern Health Clinical School, Monash University, Australia.